[Primary cervical cancer screening].
| Autor: | Vargas-Hernández VM; Dirección de Investigación, Hospital Juárez de México D.F., México. Electronic address: vvargashernandez@yahoo.com.mx., Vargas-Aguilar VM; Hospital de Oncología, Centro Médico Nacional siglo XXI, Instituto Mexicano del Seguro Social, México., Tovar-Rodríguez JM; Dirección de Investigación, Hospital Juárez de México D.F., México. |
|---|---|
| Jazyk: | Spanish; Castilian |
| Zdroj: | Cirugia y cirujanos [Cir Cir] 2015 Sep-Oct; Vol. 83 (5), pp. 448-53. Date of Electronic Publication: 2015 Jul 07. |
| DOI: | 10.1016/j.circir.2014.09.001 |
| Abstrakt: | Cervico-uterine cancer screening with cytology decrease incidence by more than 50%. The cause of this cancer is the human papilloma virus high risk, and requires a sensitive test to provide sufficient sensitivity and specificity for early detection and greater interval period when the results are negative. The test of the human papilloma virus high risk, is effective and safe because of its excellent sensitivity, negative predictive value and optimal reproducibility, especially when combined with liquid-based cytology or biomarkers with viral load, with higher sensitivity and specificity, by reducing false positives for the detection of cervical intraepithelial neoplasia grade 2 or greater injury, with excellent clinical benefits to cervical cancer screening and related infection of human papilloma virus diseases, is currently the best test for early detection infection of human papillomavirus and the risk of carcinogenesis. (Copyright © 2015 Academia Mexicana de Cirugía A.C. Published by Masson Doyma México S.A. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|